open access

Vol 12, No 5 (2016)
Published online: 2017-03-08
Get Citation

Current literature review

Maciej Kawecki
DOI: 10.5603/OCP.2016.0014
·
Oncol Clin Pract 2016;12(5):197-200.

open access

Vol 12, No 5 (2016)
Published online: 2017-03-08

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Current literature review

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 5 (2016)

Pages

197-200

Published online

2017-03-08

DOI

10.5603/OCP.2016.0014

Bibliographic record

Oncol Clin Pract 2016;12(5):197-200.

Authors

Maciej Kawecki

References (6)
  1. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19): 1856–1867.
  2. Chow LQM, Haddad R, Gupta S, et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 [Epub ahead of print].
  3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823–1833.
  4. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017; 317(1): 48–58.
  5. Janku F, Johnson LK, Karp DD, et al. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016; 27(11): 2032–2038.
  6. Choueiri TK, Halabi S, Sanford B, et al. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Annals of Oncology. 2016; 27(suppl_6).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl